新辅助动脉内减瘤化疗治疗泪腺腺样囊性癌:三模式策略的长期随访研究
该研究对19例接受新辅助动脉内减瘤化疗(IACC)、眶内容物剜除、放化疗及辅助静脉化疗的泪腺腺样囊性癌患者进行长期随访,比较有无完整泪腺动脉两组及既往常规治疗患者。结果显示完整泪腺动脉组15年总生存率87.5%显著优于既往常规治疗组的14.3%,切缘阳性增加全因死亡风险4.1倍。
要点
- 完整泪腺动脉组15年总生存率87.5%,显著优于既往常规治疗组的14.3%(P<.001)。
- 切缘阳性患者全因死亡风险为切缘阴性者的4.1倍(P=.036),疾病特异性死亡风险为8.0倍(P=.043)。
- 既往肿瘤切除伴侧壁骨切开术及未完全遵循方案要素是不良预后因素。
核心结论
- 延长随访并补充AJCC分期数据支持新辅助IACC作为完整泪腺动脉患者三模式治疗策略的组成部分。
- 按设计实施的方案要素似乎改善了该队列的总生存并减少了疾病复发。
- 该长期IACC数据集提示,评估当前常规及未来保眼双模式治疗的疗效可能需要至少15年随访这一关键标准。
研究设计与样本
- 非随机、回顾性、干预性病例系列研究。
- 纳入同一机构连续19例接受新辅助动脉内减瘤化疗(IACC)、眶内容物剜除、放化疗及辅助静脉化疗的患者。
- 分析局部区域复发和远处转移、无病生存时间、就诊时TNM肿瘤分期、对IACC的反应及切缘阳性的预后影响。
主要发现
- 完整泪腺动脉组(第1组,8例,AJCC分期T4a-c 7例)15年总生存率87.5%,既往常规治疗患者为14.3%,差异有统计学意义(P<.001,log-rank检验)。
- 第1组在总生存(P=.042)和复发(P=.017)方面优于无完整泪腺动脉的第2组,但疾病特异性死亡无显著差异(P=.23)。
- 第2组疾病特异性死亡显著低于机构对照组的相应死亡率(P=.039)。
- 切缘阳性患者全因死亡风险为切缘阴性者的4.1倍(P=.036,分层Cox比例风险回归),疾病特异性死亡风险为8.0倍(P=.043,分层Cox比例风险回归)。
临床怎么用
- 作者认为,延长随访并补充AJCC分期数据支持新辅助IACC作为完整泪腺动脉患者三模式治疗策略的组成部分。
- 作者认为,按设计实施的方案要素似乎改善了该队列的总生存并减少了疾病复发。
- 作者认为,该长期IACC数据集提示评估当前常规及未来保眼双模式治疗的疗效可能需要至少15年随访这一关键标准。
局限性
- 本研究为非随机、回顾性、干预性病例系列研究。
- 研究在单一机构进行。
- 样本量为19例。
- 作者指出该长期IACC数据集提示评估疗效可能需要至少15年随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the therapeutic efficacy of integrating neoadjuvant chemotherapy with conventional bimodal therapies for lacrimal gland adenoid cystic carcinoma by providing an additional 8 years of follow-up data on the same cohort of patients whose cumulative 10-year disease-free survival outcomes were reported in 2013. DESIGN: Non-randomized, retrospective, interventional case series. METHODS: Nineteen consecutive patients treated with neoadjuvant intra-arterial cytoreductive chemotherapy (IACC), orbital exenteration, chemoradiotherapy, and adjuvant intravenous chemotherapy at a single institution were included. Analyses were undertaken of locoregional recurrences and distant metastases, disease-free survival time, TNM tumor stage at presentation, response to IACC, and prognostic impact of positive resection margins. The main outcome measures were overall survival, disease-free survival, disease relapse, positive tumor resection margins, and tumor stage at presentation. RESULTS: Eight patients with an intact lacrimal artery (group 1), 7 with AJCC stage T4a-c, had significantly better overall survival (87.5% versus 14.3% at 15 years), disease-specific mortality, and recurrences (all < .001, log-rank test) than prior conventionally treated patients from the Bascom Palmer Eye Institute. Group 1 was superior to group 2, patients lacking an intact lacrimal artery, concerning overall survival (P = .042) and recurrence (P = .017), but with no significant difference in disease-specific mortality (P = .23). Group 2 was associated with a significantly lower cause-specific mortality than the institutional comparator group (P = .039). Prior tumor resection with lateral wall osteotomy and failure to adhere to all protocol elements were adverse prognostic factors for suboptimal outcomes. Positive tumor margins increased the risk of all-cause mortality 4.1 times (P = .036, stratified Cox proportional hazards regression) and disease-specific mortality 8.0 times (P = .043, stratified Cox proportional hazards regression) than a patient with negative margins. CONCLUSIONS: Extended follow-up supplemented with AJCC staging data supports neoadjuvant IACC as an integral component of a trimodal treatment strategy in patients with an intact lacrimal artery. Protocol elements implemented as designed appear to have improved overall survival and decreased disease relapse in this cohort. This extended long-term IACC dataset suggests that a critical bar of at least 15 years of follow-up is appropriate for assessing the efficacy of current conventional and future globe-sparing bimodal therapies.
引用
- Tse DT, Benedetto PW, Tse BC, et al. Neoadjuvant Intra-Arterial Cytoreductive Chemotherapy for Lacrimal Gland Adenoid Cystic Carcinoma: A Long-Term Follow-up Study of a Trimodal Strategy. Am J Ophthalmol. 2022. PMID: 35381201. doi:10.1016/j.ajo.2022.03.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。